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Synopsis
We have investigated the interaction between GH (growth hormone) and GHR (GH receptor). We previously demon-
strated that a truncated GHR that possesses a transmembrane domain but no cytoplasmic domain blocks receptor
signalling. Based on this observation we investigated the impact of tethering the receptor’s extracellular domain to the
cell surface using a native lipid GPI (glycosylphosphatidylinositol) anchor. We also investigated the effect of tethering
GH, the ligand itself, to the cell surface and demonstrated that tethering either the ecGHR (extracellular domain
of GHR) or the ligand itself to the cell membrane via a GPI anchor greatly attenuates signalling. To elucidate the
mechanism for this antagonist activity, we used confocal microscopy to examine the fluorescently modified ligand and
receptor. GH–GPI was expressed on the cell surface and formed inactive receptor complexes that failed to internalize
and blocked receptor activation. In conclusion, contrary to expectation, tethering an agonist to the cell surface can
generate an inactive hormone receptor complex that fails to internalize.
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INTRODUCTION
We have been investigating the interaction of GH (growth hor-
mone) with its receptor and investigating approaches to manipu-
late receptor signalling. We observed that a patient heterozygous
for a mutation in the GHR (GH receptor) had a short stature
and GH insensitivity suggesting that the mutation created a dom-
inant negative receptor [1]. The mutation encoded a truncated
receptor that had a normal extracellular and transmembrane do-
main but lacked the essential cytoplasmic signalling domain.
We demonstrated that the dominant negative action occurred as
the truncated receptor was highly expressed on the cell surface,
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complexed with the full-length receptor, but the complex failed
to signal or internalize [2]. Based on these observations, we pro-
posed that anchoring a truncated receptor to the cell surface would
generate an antagonist and by using a synthetic lipid anchor we
demonstrated this was the case [3]. Following on from this work
we have been examining the impact of anchoring proteins us-
ing naturally occurring GPI (glycosylphosphatidylinositol) lipid
anchors.
GPI anchors are common components of the eukaryotic cell
membrane and examples include ALP (alkaline phosphatase) and
DAF (decay-accelerating factor) [4]. GPI-anchored proteins are
tethered to the cell membrane through a glycolipid moiety and
have no transmembrane or cytoplasmic domains. Recombinant
C© 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
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proteins can be engineered so as to contain a GPI-signal sequence,
which is post-translationally modified in human cells resulting in
attachment onto the plasma membrane via the GPI-anchor. GPI
anchoring can be generated by fusing the cDNA of interest with
the GPI signal sequence for a naturally occurring GPI-anchored
protein such as Thy-1 [5].
GH is a cytokine that engages two identical type 1 cytokine
GHR, and the transmembrane domains of two or more GHR mo-
lecules must associate to initiate signalling [6]. GH, produced by
the pituitary, regulates body composition, with deficiency result-
ing in short stature and excess in gigantism and acromegaly [7]. In
this paper, we have examined the impact on signalling of express-
ing a fusion of the ecGHR (extracellular domain of GHR) with
a GPI anchor and also asked the question; what would happen
if we anchored the ligand itself to the cell surface? As expec-
ted, anchored receptor blocked signalling but to our surprise we
found that the anchored ligand also blocked receptor signalling
and internalization.
EXPERIMENTAL
Plasmids
The reporter construct pUC18–LHRE (lactogenic hormone re-
sponse element)–Luc, containing STAT5 (signal transducer and
activator of transcription 5) binding element, LHRE fused to
the minimal tk (thymidine kinase) promoter and the firefly lu-
ciferase cDNA (GHR) has been described previously [2]. The
phRL-CMV expression vector, encoding RL (Renilla luciferase)
under control of the CMV (cytomegalovirus) promoter, was from
Promega. The expression vector pCR3.1gpi, encoding the mam-
malian Thy-1 GPI signal sequence under control of the CMV
promoter was a gift from C. Beghadi (University of Lausanne,
Lausanne, Switzerland). The cDNAs encoding human GH and
the ecGHR were cloned without stop codons upstream of the Thy-
1 GPI signal sequence in pCR3.1gpi to generate the ecGHR–GPI
and GH-GPI constructs. The human GH cDNA was cloned in the
same vector to generate the wtGH (wild-type GH) construct, en-
coding non-anchored wtGH. GH–LL (long linker)–GPI was gen-
erated by insertion in GH–GPI of a sequence encoding a flexible
LL consisting of five repeats of a Gly4Ser (tetraglycine-serine)
motif between the coding sequences of GH and the Thy-1 signal
sequence. The GHR–GFP (green fluorescent protein) construct,
encoding the full-length GHR fused at its C-terminal end to the
GFP, was generated by inserting the open GHR coding sequence
into the pTagGFP vector (Evrogen). The GH–RFP (red fluor-
escent protein) construct, encoding GH fused at its C-terminal
end to the RFP, was made by inserting the open GH coding se-
quence into pTagRFP. Adding the Thy-1-GPI signal to GH–RFP
then generated the GH–RFP–GPI construct. All the constructs
were subjected to DNA sequencing carried out within our Core
Genetics Facility (Faculty of Medicine, Dentistry and Health,
University of Sheffield).
Flow cytometry
HEK (human embryonic kidney)-293 cells were transiently tran-
sected using calcium phosphate (Invitrogen). Detection was by
monoclonal antibodies to GHR (2C8) and GH (7F8) both kind
gifts from Professor C.J. Strasburger (Campus Mitte Charite-
Universitatsmedizim, Berlin, Germany). Briefly, about 3×105
cells were washed with PBS/1 % BSA (wash buffer) and incub-
ated with 5 μg of 2C8 or 7F8 antibodies for 30 min on ice. The
cells were washed again and incubated with 1 μg of biotinylated
goat anti-Mouse IgG (Calbiochem). The cells were then washed
and incubated with 14 μl of streptavidin conjugated to R-PE
(phycoerythrin, Serotec). A final three washes were performed to
remove the residual unbound stain. PE was excited at 488 nm and
the emitted light was detected through a 585 +− 21 nm band pass
filter. Data were acquired on a FACSort flow cytometer (Bec-
ton Dickinson) using the CellQuest data acquisition and analysis
software housed in our Core Flow Cytometry Facility (Faculty
of Medicine, Dentistry and Health, University of Sheffield).
Triton X-114 phase partitioning
Transfected HEK-293 cells (1×106) producing ecGHR–GPI,
GH–GPI or GH–LL–GPI were washed in PBS and lysed in
250 μl of lysis buffer (20 mM Tris/HCl, 150 mM NaCl, 1 mM
EDTA, 2 % Triton X-114 and 0.0 005 % Bromophenol Blue). The
cells were then left on ice with frequent stirring for 20 min.
The resulting lysate was centrifuged at 13 000 g for 5 min at 0◦C
to remove cellular debris. The supernatant was incubated at 30◦C
for 5 min and then centrifuged at 4000 g for 3 min at room tem-
perature to separate the clear aqueous phase from the detergent
phase containing Bromophenol Blue.
Western blotting
Samples were separated by SDS/PAGE (12 % gels) and blot-
ted on to the PVDF membrane. The primary antibodies were
mouse anti-GHR mAb263 (Biogenesis used at a 1:2500 dilution
ratio) and anti-human GH (rabbit) polyclonal antibody [NIH (Na-
tional Institutes of Health), used at 1:10000 dilution]. The second-
ary antibodies were anti-mouse or anti-rabbit HRP (horseradish
peroxidase)-linked IgG (Amersham Pharmacia Biotech) used at
1:10000 dilution. They were detected using an enhanced chemi-
luminescence substrate (Roche Diagnostics) and light sensitive
X-ray films.
GH signalling bioassay
The luciferase reporter GH bioassay was performed as described
previously except that the phRL-CMV vector was used as a
transfection control instead of the pCH110 vector [2]. Assays
were carried out in HEK-293 cells that permanently express
GHR, called HEK-293–GHR or HEK-293 Hi unless stated oth-
erwise. The cells were plated in 12-well plates and transiently
transfected with either reporter constructs alone (50 ng/well of
pUC18–LHRE–Luc and 1 ng/well of phRL-CMV) or with re-
porter constructs plus 100 ng/well of cDNA expression plasmid,
using calcium phosphate. The cells were stimulated with GH
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Figure 1 GPI-anchored proteins associate with plasma membrane
(A–C) Detection of GPI-anchored proteins at the surface of transfected cells. HEK-293 cells were transfected with
ecGHR–GPI (A), GH–GPI (B) or GH–LL–GPI (C), labelled with antibodies to GHR or GH and subjected to flow cytometry.
Histograms from transfected cells (dark grey curves) are shown overlaid onto control histograms from untransfected cells
(light grey). (D) Phase partitioning and molecular masses of GPI-anchored proteins. Cells transfected with ecGHR–GPI,
GH–GPI or GH–LL–GPI were subjected to phase partitioning and the resulting detergent (Deter.) and aqueous (Aqu.) phases
were probed by Western blotting with antibodies to GHR or GH, as appropriate. The positions and molecular masses (kDa)
of standard proteins are shown next to the first immunoblot.
18 h after transfection, then lysed after a further 6 h. The fire-
fly and RL activities were measured using the Promega dual
luciferase reporter assay kit. The firefly luciferase values were
normalized to those of the phRL-CMV-encoded RL to correct
for variations in transfection efficiency and cell number. The res-
ults were expressed as fold-induction relative to the unstimulated
control of each plate. For experiments requiring autocrine GH
stimulation, HEK-293–GHR cells were transfected twice. The
first transfection used 100 ng/well (12-well plate) of wtGH con-
struct. The other cDNA expression constructs and the reporter
constructs were co-transfected in the second transfection 18 h
later.
Laser scanning confocal microscopy
HEK-293 cells were grown on poly-L-lysine-coated glass-
bottomed microwell culture dishes (MatTek Corporation) for 16 h
before being transfected using Lipofectamine2000 (Invitrogen).
Confocal microscopy was carried out 2 days after transfection
using a Zeiss 510 NLO laser scanning confocal microscope fitted
with ×20 NA 0.8 and ×40 NA 1.2W (water) objective lenses.
Fluorescence images of GFP were obtained using 488 nm laser
excitation, NFT490 dichroic and LP505 emission filter. Images
of RFP were obtained using 543 nm laser excitation, NFT545
dichroic and LP560 emission filters. Images were acquired at
1024×1024 (pixel dwell time 0.8 μs) pixels and 1.3 μm optical
slices. Background fluorescence was subtracted from the im-
ages using ImageJ 1.37c software (NIH) [20]. Co-localization
of fluorophores was identified by Intensity Correlation Analysis,
determining the positive product of the difference of the means
with the ImageJ plug-in developed at the Wright Cell Imaging
Facility, Toronto, Canada.
RESULTS
GPI-anchored GH proteins demonstrate cell
membrane expression
We wished to examine the impact of anchoring ecGHR and GH
to the cell surface and we also raised the question whether the
length of linker between GH and its anchor would alter bio-
logical activity. The following constructs were tested: wtGH
with no anchor (wt GH), GH linked to GPI either through
a short linker (GH–GPI) or LL (GH–LL–GPI), and ecGHR
linked to GPI (ecGHR–GPI). Flow cytometry of HEK-293 cells
transfected with the GPI-anchored proteins: GH–GPI, GH–LL–
GPI and ecGHR–GPI showed that transfection efficiencies were
>90 % and that for all the GPI-anchored proteins there was a
high but variable cell surface expression (Figures 1A–1C). The
biophysical properties of the recombinant proteins were then
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Figure 2 Inhibition of signalling by GPI-anchored proteins
(A) HEK-293–GHR cells were co-transfected with the pUC18–LHRE–Luc and phRL–CMV reporter constructs, with or without
the wtGH, ecGHR–GPI, GH–GPI or GH–LL–GPI cDNA construct, as indicated, and stimulated 18 h later with various doses
of exogenous GH. Normalized reporter levels are expressed relative to values in cells transfected with reporter constructs
only and not exposed to GH. Means +− S.E.M. of n = 4 (ecGHR–GPI, GH–LL–GPI) or n = 6 are shown. (B) HEK-293–GHR
cells were transfected with the reporter constructs but no cDNA and were then challenged with conditioned media from
untransfected cells or cDNA-transfected cells expressing ecGHR-GPI or GH–GPI, as indicated. Stimulation with exogenous
GH, reporter assays and data analysis were carried out as in (A). Means +− S.E.M. of n = 3 are shown. (C) To test the
inhibition of the autocrine GH response, HEK-293–GHR cells were pre-transfected with 100 ng of wtGH construct 18 h
before being transfected a second time with the reporter constructs and various amounts of plasmid encoding ecGHR-GPI,
as indicated. Data analysis was carried out as in (A) and (B) and one-way ANOVA with Bonferroni’s post-hoc comparison
was performed. Means +− S.E.M. of n = 6 are shown. One, two or three asterisks correspond to P< 0.05, P< 0.01 or
P< 0.001, respectively. (D) As in (C), except that the GH–GPI expression construct was used instead of ecGHR–GPI.
assessed by phase partitioning (separation of protein into either
a detergent or aqueous phase) to demonstrate the presence or
absence of a GPI anchor (Figure 1D). The recombinant pro-
teins ecGHR–GPI, GH–GPI, GH–LL–GPI migrated at their pre-
dicted molecular masses and all partitioned into the detergent-
enriched phase with no detectable protein in the aqueous
phase, as is expected for GPI-anchored proteins. These res-
ults confirmed that all the three GPI-anchored proteins were
expressed at the cell surface and retained their GPI lipid
moiety.
GPI-membrane-anchored GH and ecGHR block GH
signalling
A dual luciferase promoter–reporter bioassay for functional
ligand–receptor-mediated signalling was employed to examine
the action of GPI-anchored proteins. HEK-293 cells stably ex-
pressing human GHR (HEK-293–GHR) and transiently trans-
fected with the bioassay reporter constructs showed a dose-
dependent response to exogenously administered GH (Fig-
ure 2A). When the wtGH expression plasmid was co-transfected
with the reporter constructs, high reporter expression was seen
independent of exogenous GH, indicating that the expression of
wtGH led to autocrine/paracrine stimulation. In contrast, HEK-
293–GHR cells transfected with the anchored ecGHR, ecGHR–
GPI, showed no increase in basal reporter expression and no
response to the exogenously administered GH (Figure 2A). This
demonstrated that, as expected, ecGHR–GPI acted as an ant-
agonist. To our surprise, cells transfected with GH–GPI did
not behave like the wt-GH-transfected cells but instead showed
no increase in basal reporter expression and, like the ecGHR–
GPI-transfected cells, no response to the exogenously added
GH (Figure 2A). We questioned whether an LL between GH
and GPI could overcome any steric hindrance and restore sig-
nalling; however, the GH–LL–GPI construct inhibited the bioas-
say as effectively as GH–GPI (Figure 2A). Thus, both the GH–
GPI and GH–LL–GPI constructs behaved as antagonists of GH
signalling.
We considered the possibility that the inhibitory effects of
the GPI-linked proteins might be caused by the partial release
of these proteins into the culture medium. To examine this, we
challenged untransfected cells with GH in the presence of con-
ditioned media from cells transfected with either ecGHR–GPI
or GH–GPI. The conditioned media did not inhibit the response
to GH (Figure 2B), indicating that the ecGHR–GPI- and GH–
GPI-expressing cells were not secreting any detectable soluble
inhibitor of GH signalling.
We next examined the effect of the GPI-anchored proteins
on autocrine GH signalling. The cells were subjected to a first
transfection with wtGH and 18 h later to a second transfection
with reporter constructs and various amounts of cDNA con-
struct encoding either ecGHR–GPI (Figure 2C) or GH–GPI (Fig-
ure 2D). Control transfections in which the GPI-fusion constructs
were omitted showed that autocrine action of wtGH led to a
12-fold increase in reporter expression relative to cells not ex-
pressing the cytokine. This response was inhibited when either
ecGHR–GPI or GH–GPI was included in the second transfec-
tion and in each case, the degree of inhibition was greater as the
amount of transfected GPI construct was increased (Figures 2C
and 2D).
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Figure 3 Biological activities of the fluorescent proteins
(A) HEK-293 cells were subjected to the promoter–reporter bioassay in the absence of co-transfected cDNA or in the
presence of cDNA constructs encoding wt GHR or GHR–GFP, as indicated. (B) The activities of fluorescent labelled GH-RFP
and GH–RFP–GPI proteins were tested with the bioassay in the HEK-293–GHR-expressing cell line as had been done for
the non-fluorescent wtGH and GH–GPI in Figure 2(A). All the data were analysed as in Figure 2 and are means +− S.E.M. of
n = 4 (A) or n = 6 (B).
Signalling properties of fluorescent fusion proteins
As a preparation to investigating the mechanisms of inhibition
of GH action by the GPI fusion proteins, we generated a red-
fluorescent GPI-anchored GH (GH–RFP–GPI), a red-fluorescent
non-anchored GH (GH–RFP) and a green fluorescent receptor
(GHR–GFP) and assessed the biological activities of the fluor-
escent proteins. The activity of fluorescent labelled GHR–GFP
was assessed with the dual-luciferase promoter–reporter bioas-
say in the HEK-293 cells, which endogenously only express low
levels of GHR. In the absence of a co-transfected GHR cDNA,
the cells only show weak activation of reporter expression in
response to exogenously administered GH (maximum fold ac-
tivation 1.65 +− 0.26), but the response to the GH is dramatically
increased when they are transfected with a wt GHR cDNA con-
struct (maximum fold activation 16.9 +− 1.5, Figure 3A). A sim-
ilar but quantitatively smaller increase was observed when the
fluorescent receptor construct, GHR–GFP, was substituted for
the wtGHR (maximum fold induction 6.5 +− 0.9, Figure 3A).
The activities of fluorescent labelled GH–RFP and GH–RFP–
GPI proteins were tested in the HEK-293–GHR cell line (Fig-
ure 3B). Cells expressing GH–RFP showed constitutively high
levels of reporter expression (8.2 +− 1.5-fold activation of reporter
expression relative to cells expressing no cDNA) and this was not
significantly increased when the cells were exposed to increas-
ing amounts of exogenously administered GH (Figure 3B). Ex-
pression of GH–RFP–GPI activated reporter expression, albeit
to a lesser extent than that observed in cells expressing GH–
RFP (5.7 +− 0.7-fold activation). This intermediate level of re-
porter activity suggested that the expression of GH–RFP–GPI
partially activated the GH signalling machinery; however, no
significant increase in reporter activation was observed when
the cells expressing GH–RFP–GPI were exposed to increas-
ing doses of exogenous GH (Figure 3B). This suggested that
while GH–RFP–GPI differed from GH–GPI and GH–LL–GPI
by being a partial agonist, it shared with the other GPI con-
structs the ability to block the action of exogenously administered
GH.
GPI-anchored GH forms cell surface complexes
with wt receptor
To examine the interaction between GH–GPI and GHR, we mon-
itored the localization of the fluorescent fusion proteins by laser
scanning fluorescence microscopy. We first characterized the dis-
tribution of each fluorescent protein when transfected by itself
(Figure 4). Cells transfected with GHR–GFP showed fluores-
cence both on the cell membrane and within the cytoplasm (Fig-
ure 4A), in a pattern comparable with previous data showing
trafficking of GFP-tagged GHR from the ER (endoplasmic re-
ticulum) via the Golgi apparatus to the cell membrane [8]. In
cells transfected with the non-anchored GH–RFP fusion protein,
red fluorescence was detected predominantly in discrete struc-
tures within the cytoplasm. We considered that this distribution
could be either GH–RFP packaged for secretion or GH–RFP
that had been secreted and then bound receptor and internalized
(Figure 4B). To discriminate between these two alternatives, we
applied conditioned media from GH–RFP transfected cells to
untransfected HEK-293–GHR cells. The untransfected cells
then showed the presence of GH–RFP in discrete intracellular
structures, which confirmed that the fluorescent agonist had been
secreted by the transfected cells and internalized by the imaged
cells (Figure 4C). Similar localization of the red fluorescence in
Figures 4(B) and 4(C) suggests that in the GH–RFP-expressing
cells (Figure 4B) at least a fraction of the intracellular fluores-
cence probably corresponds to GH–RFP internalized after secre-
tion. In contrast to GH-RFP, the GH–RFP–GPI fusion protein
was localized predominantly on the cell membrane with only a
small proportion present within the cytoplasm, suggesting little
or no internalization (Figure 4D).
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Figure 4 Intracellular localization of fluorescent fusion proteins
(A, B) HEK-293 cells imaged after transfection with either the green fluorescent GHR fusion construct, GHR–GFP (A) or
the red fluorescent cytokine construct, GH–RFP (B). (C) HEK-293 cells that have not been transfected were imaged after
a 3 h incubation in conditioned media from the GH–RFP-expressing cells. The intracellular red fluorescence indicates
that the cells had internalized GH–RFP present in the conditioned media from the GH–RFP-expressing cells. (D) HEK-293
cells imaged after transfection with the GPI-anchored fluorescent GH construct, GH–RFP–GPI. Each confocal fluorescence
image is shown both alone (left) and overlaid onto a phase contrast image of the same field (right). In contrast, anchored
GH–RFP–GPI is predominantly found on the cell surface (C).
To analyse the interactions between the GH constructs and
the GH receptor, we then co-transfected the GH–RFP expres-
sion plasmid with the GH-based constructs (Figure 5). In cells
co-transfected with GHR–GFP and GH–RFP, the recombinant
receptor showed both membrane and cytoplasmic localizations
(Figure 5A). However, in contrast to what had been observed
in the single transfection experiments (Figure 4A), the intracel-
lular pool of GHR–GFP molecules was not evenly distributed
throughout the cytoplasm but appeared instead to accumulate in
discrete intracellular locations (Figure 5A) similar to that seen
for internalized GH–RFP from media (Figure 4C). Overlaying
the red and green fluorescent images showed that a fraction
of the GHR–GFP pool co-localizes with GH–RFP (Figure 5C),
and this was confirmed by the co-localization analysis (Fig-
ure 5D). Similar results were observed when culture media
containing non-anchored GH–RFP were added to GHR–GFP-
transfected cells (Figures 5G–5K). These results are entirely
consistent with the distributions of GH–RFP observed previ-
ously in cells that were not expressing GHR–GFP (Figures 4B
and 4C). They indicate that co-localization of GH–RFP and
the receptor reflects internalization of the receptor–hormone
complex.
We then observed the distributions of co-transfected GHR–
GFP and GH–RFP–GPI (Figures 5I–5L). The results show that
the two pools of fluorescent proteins are entirely co-localized,
with the majority of each construct being located on the cell mem-
brane and only a minor fraction of each pool adopting an intra-
cellular distribution (Figure 5I–5L). Thus, GH–RFP-GPI forms
a complex with GHR–GFP on the cell surface, which does not
internalize.
DISCUSSION
We have examined the interaction between GH and its receptor
and investigated the impact of anchoring either the extracellular
domain of the receptor or the GH ligand itself to the cell surface
via attachment of an endogenous GPI anchor. Both the receptor’s
extracellular domain and ligand blocked receptor signalling when
tethered to the cell membrane through a GPI anchor.
GH binding to its receptor results in a conformational change
that includes rotation in the transmembrane domain and trig-
gers signalling and internalization [9]. We questioned whether
increasing the length of linker to the cell membrane could restore
agonistic activity to our GPI-anchored hormone, as too short a
linker could restrict the movement of the molecule. However,
the GH–LL–GPI construct inhibited GH signalling as efficiently
as GH–GPI despite the presence of a 70 ˚A (1 ˚A = 0.1 nm) long
glycine/serine-rich linker that was intended to relieve any con-
formational or spatial restraints between the GH moiety and the
GPI domain.
Experiments with the fluorescent receptor, GHR–GFP and the
non-anchored fluorescent ligand, GH–RFP, showed that fluores-
cent tagging of GH and its receptor did not interfere with traf-
ficking of the receptor to the cell surface, formation of receptor–
cytokine complexes and internalization of the complexes.
GH–RFP–GPI anchored to the cell surface still formed a ligand–
receptor complex but was not internalized. The partial activation
of signalling seen by GH–RFP–GPI could be a steric action of
RFP or the introduction of RFP might result in a small proportion
of the molecule being proteolysed and releasing free GH.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
658 C© 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
by-nc/2.5/) which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
GPI-anchored cytokine antagonists
Figure 5 GPI-anchoring of GH blocks GHR internalization
This Figure examines the co-localization of GHR and GH with and without GPI-anchored GH–GPI. In cells co-expressing
the non-anchored GHR–GFP (A, C, D) and GH–RFP (B–D) proteins, a fraction of the GHR–GFP pool co-localizes with the
GH–RFP inside cells (A–D). Co-localization is indicated by yellow colouring in the overlay image (C) and is confirmed in
the intensity correlation image (D). The same distributions are observed when cells expressing GHR–GFP only are incubated
with exogenously provided GH–RFP (E–H), indicating that intracellular co-localization reflects the internalization of the
receptor–ligand complexes. By contrast, when GHR–GFP is co-expressed with the anchored GH–RFP–GPI (I–L), neither
protein is internalized.
The cytoplasmic domain of the GHR is essential not only for
activating the GHR but also for triggering internalization of the
hormone receptor complex [10]. However, signalling is not re-
quired for receptor internalization as a receptor with a mutated
cytoplasmic domain that fails to signal still internalizes [11], and
the GH antagonist Pegvisomant binds the receptor dimer, pre-
vents signalling but is internalized [12]. Truncated receptors that
lack a cytoplasmic domain act as dominant negative inhibitors
of signalling not only because they heterodimerize with the full-
length receptor but also because they prevent internalization and
therefore accumulate on the cell surface [2]. It has been repor-
ted that both GH and its receptor may translate to the nucleus
and correlate with proliferative activity [13]; thus a failure of the
hormone receptor complex to internalize could again prevent
the biological activity of GH. Our results suggest that GH–GPI
not only occupies the receptor to prevent signalling but also holds
the receptor complex at the cell surface. GHR is present in ca-
veolae and lipid rafts which are lipid-rich microdomains of the
plasma membrane [14,15]. Various membrane proteins are con-
centrated in these lipid microdomains including GPI-anchored
proteins such as the Thy-1 cell surface antigen [16]. Thus, GPI
anchoring of GH or ecGHR increases the probability that the
GPI-anchored proteins will co-segregate with the native GHR on
the cell membrane and constrain the GHR in a conformation that
cannot be readily internalized.
In some cell types, autocrine actions of GH are more potent
than exogenously administered GH [17–19]. Moreover, autocrine
GH producing cells become unresponsive to externally admin-
istered GH [20,21]. Both GH–GPI and ecGHR–GPI inhibited
the action of intracellularly generated GH, and by increasing the
ratio of GH–GPI to wtGH, the inhibition was increased although
never complete. However, it should be recognized that trans-
fection experiments result in relatively high expression levels
of endogenous GH compared with physiological conditions. We
attempted to purify ecGHR–GPI and GH–GPI and investigate
whether the GPI fusions could be re-inserted into the cell mem-
branes, however despite repeated attempts we were unable to
purify the proteins (results not shown). This may relate to either
the presence of a lipid moiety or the low level of expression of
cell surface proteins.
Our findings show that tethering a cytokine agonist to the
cell surface using endogenously generated GPI anchors results in
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an antagonist. Such a strategy could potentially be applied to a
wide range of cytokines that act through the cell surface receptors
providing a technology that could be used to manipulate cytokine
signalling in the laboratory.
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